Evotec lowers FY25 revenue forecast, keeps profit targets & confirms long-term 2028 outlook
Source: SeekingAlpha
2025-07-21 06:47:44 ET
Evotec ( OTCPK:EVOTF ) announced an update to its fiscal year 2025 revenue guidance, now expecting €760-€800 million (down from €840-€880 million)....
Read the full article on Seeking Alpha
For further details see:
Evotec lowers FY25 revenue forecast, keeps profit targets & confirms long-term 2028 outlook
Evotec SE
NASDAQ: EVOTF
EVOTF Trading
177900.0% G/L:
$8.01 Last:
2,814 Volume:
$8.01 Open:
EVOTF Latest News
March 19, 2026 02:50:00 am
Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation
January 08, 2026 01:50:00 am
Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access
January 02, 2026 12:30:00 am
Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations
December 08, 2025 01:20:00 am
Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz
EVOTF Stock Data
$326,390,317
157,381,715
N/A
374
N/A
Biotechnology & Life Sciences
Healthcare
DE
Hamburg
